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Patientswithinﬂammatoryboweldisease(IBD)faceanincreasedlifetimeriskofdevelopingcolorectalcancer(CRC).Independent
factors associated with increased risk include long disease duration, extensive colonic involvement, young age at onset of IBD,
severity of inﬂammation, primary sclerosing cholangitis, backwash ileitis, and a family history of CRC, thus emphasising the role
of intestinal inﬂammation as an underlying mechanism. This notion is also supported by the demonstration that the use of certain
drugs used to attenuate the ongoing mucosal inﬂammation, such as mesalazine, seems to associate with a reduced incidence of
colitis-associated CRC. In the last decade, work from many laboratories has contributed to delineate the mechanisms by which
mesalazine alters CRC cell behaviour. In this paper, we review the available experimental data supporting the ability of mesalazine
and its derivatives to interfere with intracellular signals involved in CRC cell growth.
1.Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD), the major
forms of inﬂammatory bowel diseases (IBDs) in humans, are
chronic inﬂammatory disorders of the gastrointestinal tract
[1]. In UC, inﬂammation is restricted to the mucosa and
extends proximally from the rectum to involve all or part of
thecolon.CDistypicallyapatchy,transmural,inﬂammatory
disease that can aﬀect the gastrointestinal tract anywhere
from the mouth to the anus. Both IBDs are characterized by
episodes of remission and exacerbations in which the patient
experiencesabdominalpain,diarrhea,bloodinthestool,and
systemic symptoms [1]. Patients with long-standing disease
and severe inﬂammatory lesions involving the entire colon
have increased risk of developing colorectal cancer (CRC)
[2–4]. A family history of CRC, the presence of primary
sclerosing cholangitis, backwash ileitis, and, in some studies,
young age at onset of colitis increase further the risk of
IBD-associated CRC [5–8]. CRC complicating the natural
history of IBDs accounts for only 1-2% of all cases of CRC
[9]. Nonetheless, chronic colitis is among the top high-risk
conditions for CRC, and IBD patients are 6 times more likely
to develop CRC than the general population [10].
Unlike sporadic CRC in which the dysplastic precursor
is usually the adenomatous polyp, IBD-associated dysplasia
can be both polypoid and ﬂat, localized or diﬀuse, and this
probably reﬂects the fact that carcinogenesis in the inﬂamed
colon follows a diﬀerent sequence of genetic alterations
than that observed in sporadic CRC [11] .T h eg o a lo fC R C
screening and surveillance colonoscopy in IBD population
is detection of premalignant changes early enough that
intervention can prevent complications of invasive cancer.
Unfortunately,however,surveillanceprogramshavenotsub-
stantially prolonged survival in IBD patients, due to the
technical limitations of recognizing dysplastic lesions in ﬂat,
normal-appearing mucosa [12]. This clearly suggests the
need of alternative strategies of chemoprevention.
Over the last decades, the advent of sophisticated tech-
niques of molecular biology has contributed to the identi-
ﬁcation of key steps in the process of colon carcinogenesis,
thereby facilitating the development of new drugs that eﬃ-
ciently target malignant cells. Some of these compounds,
such as nonsteroidal anti-inﬂammatory drugs (NSAIDs) and
selective inhibitors of cyclooxygenase (COX)-2, are eﬀective
inattenuatingthegrowthanddiﬀusionofCRCcells[13,14].2 Journal of Biomedicine and Biotechnology
However,theiruseinthechemopreventiveprogramsofIBD-
related CRC is not justiﬁed because the administration of
NSAIDsandCOX2-inhibitorsinIBDpatientsassociateswith
high risk of disease ﬂare-ups [15, 16].
Mesalazine or 5-aminosalicylic acid (5-ASA) is a drug
widely used in IBDs, mainly UC, for the treatment of mild
relapses and maintenance of remission. Mesalazine is struc-
turally related to NSAIDs, but unlike these compounds, it
is safe and free of serious adverse eﬀects. Epidemiological
observations indicate that mesalazine can be also chemopre-
ventive for IBD-associated CRC [4, 17, 18], even though
one study has documented no beneﬁt [19]. Moreover studies
conducted in experimental models of carcinogenesis have
shown that the drug has many targets in cancer cells and
modulates multiple biological pathways that sustain CRC
[20]. In this paper we review the available experimental data
that demonstrate the ability of mesalazine and its derivatives
to interfere with intracellular signals involved in CRC cell
growth.
2.MesalazineInhibitsCRCCell
GrowthandSurvival
The process of carcinogenesis is facilitated by a complex
and dynamic interaction between genes and environmental
factors that ultimately aﬀects cell growth and survival. As a
matter of fact, apoptosis progressively decreases and prolif-
eration increases in the sequential steps from normal colonic
mucosa to dysplasia and CRC. Therefore, compounds that
inhibit cell proliferation and/or enhance cell apoptosis could
ﬁnd a place in the therapeutic armamentarium for CRC.
The initial demonstration that mesalazine can block the
growth and promote apoptosis of CRC cells comes from ex
vivo studies in patients with colonic adenoma. Reinacher-
Schick et al. showed that mesalazine administered orally to
patients with sporadic polyps increased the apoptotic rate
and decreased proliferation of cancer cells [21]. Bus et al.
demonstrated that rectal administration of mesalazine in
patients with sporadic CRC enhanced apoptosis of tumor
cells [22]. These observations were supported by studies
in the mouse model of colitis-associated CRC, induced by
administration of azoxymethane (AOM) followed by re-
peated oral administration of dextran sulfate sodium (DSS),
which showed that mesalazine reduced the number and size
of neoplasms [23, 24].
It is conceivable that the anti-neoplastic properties of
mesalazine are in part linked to the ability of the drug to
target mucosal immune cells and inhibit expression and/or
activityofvariousmoleculesinvolvedincoloncarcinogenesis
(e.g., COX-2, inducible nitric oxide synthase, reactive oxygen
species and nuclear factor-kB). However, mesalazine could
also regulate directly the activity of neoplastic cells. Indeed,
it has been shown that mesalazine inhibits the growth and
enhances the apoptosis of several CRC cell lines in a time-
and dose-dependent manner [25]. The anti-mitogenic eﬀect
of mesalazine is also seen in COX-2-deﬁcient cells raising the
possibility that mesalazine inhibits CRC cell growth via both
COX-2-dependent and independent mechanisms [26].
Mesalazine-induced antiproliferative eﬀect is associated
with modulation of replication checkpoints in CRC cells,
which ultimately alter cell cycle progression. In this context,
we have shown that increasing concentrations of mesalazine
(i.e., 5–30mM) cause a progressive accumulation of CRC
cells in S phase, thereby decreasing the percentage of cells in
G2/M and G0/G1 [27]. Mesalazine-treated cells exhibit a
reduced expression of the phosphatase CDC25A, but not
CDC25B or CDC25C, and inactivation of CDK2, a target
of CDC25A [27]. Since CDK2 binds to either cyclin E or
cyclin A and regulates the G1/S transition and S phase pro-
gression, respectively [28], mesalazine-induced CDK2 inac-
tivation could be responsible for cell cycle block in S-phase.
The exact mechanism by which mesalazine down-regulates
CDC25A expression is not yet known. It is unlikely that
CHK1 and CHK2, two upstream kinases that phosphorylate
and promote degradation of CDC25A are involved in the
negative regulation of CDC25A, because mesalazine down-
regulates CDC25A, expression in CHK1- or CHK2-deﬁcient
cells [27]. By contrast, we showed that cells treated with
mesalazine displayed enhanced ubiquitination and protea-
some-dependent degradation of CDC25A [27]. These ﬁnd-
ings together with the demonstration that mesalazine does
not aﬀect CDC25A RNA expression strongly suggest that
CDC25A is posttranscriptionally down-regulated in mesal-
azine-treated cells. These results are consistent with those
publishedbyLucianiandcolleagues,whoshowthatexposure
of CRC cells to mesalazine causes a reversible accumulation
of cells in S-phase [29]. These authors showed that such
an eﬀect was p53 independent and related with the acti-
vation of proteins involved in the ATM- and Rad3-related
kinase-(ATR-)dependentS-phasecheckpointresponse(e.g.,
Chk1, RAD17) [29]. Further work by other researchers has
conﬁrmed the ability of mesalazine to interfere with cell
cycle progression [30, 31] and shown that CRC cells can
accumulate in various phases of the cell cycle in relation to
the dose and time of exposure to the drug.
3. Effects of Mesalazine onReplication Fidelity
Both sporadic and IBD-related CRC are characterized by a
very similar frequency of the two major types of genomic
instability, namely, chromosomal instability (CIN) and
microsatellite instability (MIN) [32]. CIN is characterized by
atypical segregation of chromosomes and abnormal DNA
content (aneuploidy), with consequent loss of whole (or part
of) chromosomes and function of critical tumor suppressor
genes (e.g., adenomatous polyposis coli, p53). MIN is charac-
terized by an increased rate of point mutations and is depen-
dent on defects in the mismatch repair system, a mechanism
involved in repairing DNA base-pair mismatches, which
occur in the normal DNA replication. During this process,
frameshift mutations, called microsatellites, tend to accumu-
late. Microsatellites occur mainly in intronic DNA sequences
thus resulting in no gene function alteration. However, when
microsatellites are located in exonic gene regions, there can
be a shift in the codon reading frame which results in a
loss of protein function [33]. Studies performed by GascheJournal of Biomedicine and Biotechnology 3
and Campregher demonstrated that mesalazine improves
replicationﬁdelityinculturedCRCcellsindependentlyofthe
presenceofmismatchrepairsystem[34,35].Themechanism
by which mesalazine inhibits the generation of frameshift
mutations remains unknown, even though it could in part
rely on the ability of the drug to slow down DNA replication
and cell division [29], because cell cycle regulation is one of
the defense mechanisms that allow cells to either repair DNA
damage or eventually undergo apoptosis thus safeguarding
the integrity of the genome [36].
4.MesalazineInhibitsWnt/β-Catenin
Pathwayand EGFRActivation
An intriguing possibility that emerges from the available
experimental data is that the antitumoral properties of
mesalazine reﬂect the ability of the drug to target several
pathways that are both early and common in colorectal car-
cinogenesis. The Wnt/β-catenin pathway, which is consti-
tutively activated in the majority of CRC, is one of such
targets. In this pathway, Wnt binds to the transmembrane
Frizzled receptor, leading to the activation of the cytoplasmic
disheveled (Dsh) protein. Dsh forms a complex with the
β-catenin degradation complex, which consists of the APC
gene product, glycogen synthase kinase-3β (GSK-3β), axin,
and β-catenin. In the absence of Wnt, GSK-3β phospho-
rylates β-catenin, thereby promoting its ubiquitination and
degradation [37]. In response to Wnt signals, β-catenin is
no longer targeted for degradation, and it accumulates in
the cytoplasm and subsequently translocates to the nucleus,
where it associates with the transcriptional enhancers of the
lymphoid enhancer-binding factor/Tcf family and stimulates
the expression of genes involved in tumor progression [37].
Bos and colleagues showed that mesalazine inhibits the
Wnt/β-catenin pathway in APC-mutated CRC cells with
intact β-catenin [38]. Mesalazine increases β-catenin phos-
phorylation and consequently reduces nuclear accumulation
of β-catenin and expression of Wnt/β-catenin target genes
(e.g., cyclin D1, c-met, and c-Myc) [38]. The mechanism
by which mesalazine promotes β-catenin phosphorylation
remains to be ascertained, but it is known that the drug
inhibits the activity of the protein phosphatase (PP)2A [38],
aknownregulatoroftheβ-cateninphosphorylationstatusin
CRC cells [39].
Another important target of mesalazine in CRC cells
is epidermal growth factor receptor (EGFR), the activation
of which is followed by a range of intracellular events that
eventually stimulate CRC growth and survival [40]. EGFR
is overexpressed not only in sporadic CRC but also in the
premalignant lesions of IBD-associated carcinogenesis [41,
42]. We showed that mesalazine suppresses EGFR phospho-
rylation/activation in CRC cells, as a result of its ability to
enhance the activity of protein tyrosine phosphatases (PTPs)
that control EGFR activation [43]. In particular, mesalazine
induces Src homology (SH)-PTP2 to interact with and
promote dephosphorylation of EGFR [43].
5.MesalazineActivatesPPAR-γ inCRCCells
The peroxisome-proliferator-activated receptor gamma
(PPAR-γ), a transcription factor belonging to the nuclear
hormone receptor superfamily, is highly expressed in the
colonwhereitregulatescellularproliferation,diﬀerentiation,
and apoptosis [44]. PPAR-γ activation inhibits formation
of aberrant crypts foci and development of CRC in mice
[45, 46]. Rousseaux et al. showed that PPAR-γ is a target
of mesalazine in CRC cells [47]. Speciﬁcally, mesalazine
enhances PPAR-γ expression, promotes its translocation
from the cytoplasm to the nucleus, and increases its inter-
action with vitamin D3 receptor-interacting protein-205 in
CRC cells [47]. In competitive binding studies, mesalazine
displaces rosiglitazone and the selective PPAR-γ ligand
GW1929 from their binding sites on the PPAR-γ molecule
[47]. In immune-deﬁcient mice engrafted with human CRC
cells, administration of mesalazine reduces the growth of
xenografts, via a PPAR-γ-dependent mechanism [48].
Activation of PPAR-γ by mesalazine is accompanied by
induction of the tumor suppressor gene PTEN, activation
of caspase-8 and caspase-3, and diminished expression of
survivin and X-linked inhibitor of apoptosis protein [49].
6.AntineoplasticEffects of
MesalazineDerivatives
Before generally considering mesalazine as an antitumor
compound, it should be taken into consideration that the
majority of preclinical studies investigating the role of this
drug in CRC growth and survival have been conducted in
experimental models using very high doses which are not
commonly reached within the gut tissue under standard
oral treatment. Therefore, the validation of novel mesalazine
derivatives that exhibit similar safety proﬁles but enhanced
anticancer activity is highly desirable.
To this end, we have recently developed several mesal-
azine derivatives and focused our work on 2-methoxy-5-
amino-N-hydroxybenzamide (we termed 2–14), since this
compound displayed the more pronounced antimitogenic
eﬀe c ta n dw a st e nt i m e sm o r ep o t e n tt h a nm e s a l a z i n e
in blocking CRC cell growth [50]. Interestingly, 2–14 did
not aﬀect the growth of normal colonic intraepithelial
lymphocytes and ﬁbroblasts [50]. Unlike mesalazine, 2–
14 induced endoplasmic reticulum stress (ERS) in CRC
cells thereby promoting downregulation of cyclin D1 and
accumulation of cells in G0/G1 phase of the cell cycle [50].
As expected, persistent block of 2–14-treated CRC cells in
G0/G1 phase of cell cycle was accompanied by a caspase-
dependent cell death [50]. To translate these observations
in vivo, we assessed the anti-neoplastic eﬀe c to f2 – 1 4i na
syngeneic CRC model, in which tumors were generated by
injecting the murine CRC cell line, CT26, into Balb/c mice.
Micetreatedwith2–14showedaremarkabledose-dependent
decrease in tumor volume compared to control mice [50].
The anticancer eﬀects of 2–14 was documented regardless
of whether the drug was administered subcutaneously or
systemically while in the same model mesalazine reduced4 Journal of Biomedicine and Biotechnology
the growth of tumors only when given subcutaneously [50].
We further strengthened the in vivo anti-neoplastic eﬀect
of 2–14 by using the AOM/DSS-induced colitis-associated
CRC. Mice given 2–14 developed fewer smaller tumors than
control mice and 2–14 treatment was not associated with
signiﬁcantchangesintheproliferationrateofnormalcolonic
cells[50].Morerecently,weshowedthat2–14sensitizedCRC
cells to TNF-related apoptosis-inducing-ligand- (TRAIL-)
driven death [51]. TRAIL-driven cancer cell apoptosis is
mediated by ligand-dependent activation of two functional
deathreceptors(DRs)(i.e.,DR4andDR5)[52].Treatmentof
TRAIL-resistant CRC cells (i.e., HT-29 and DLD-1) with 2–
14butnotmesalazineupregulatedDR5[51].Moreover,2–14
down-regulated the expression of survivin, an antiapoptotic
protein that interferes with TRAIL-induced cell death in
cancercells[53].Theseinvitrodatawereconﬁrmedinagraft
modelgeneratedbyTRAIL-resistantCRCcells(i.e.,CT26)in
mice.Inthismodel2–14synergizedwithTRAILininhibiting
the in vivo growth of CT26-derived tumors [51]. In line with
our results, Honeder and coworkers have recently showed
that mesalazine derivatives, including 2–14, inhibit CRC cell
growth [54].
7. Conclusion
In the last decade extensive research has been performed to
evaluate the anti-neoplastic action of mesalazine. Although
deﬁnitive conclusions from these studies cannot be drawn,
it seems that when used at very high doses the drug can
interfere with critical steps in the process of colon car-
cinogenesis. Even more promising seem to be the results
obtained with mesalazine derivatives. Among these, 2–14 is
more potent than mesalazine in inhibiting CRC cell growth
and survival, maintains its anti-tumor activity when admin-
istered systemically, and does not aﬀect the proliferation
of normal gut cells. These observations and the fact that
2–14 is fully synthetic and has a fairly simple structure
suggest that this drug could be helpful in designing novel
CRC chemoprevention programs. Further experimentation
is however needed to deﬁne the pharmacokinetic properties
of the compound and evaluate the potential eﬀects of 2–14
on vital functions of the host.
Acknowledgments
This work received support from the “Fondazione Umberto
di Mario”, Rome, AIRC (Grant no. 9148), and Giuliani SpA,
Milan, Italy.
References
[1] C. Abraham and J. H. Cho, “Inﬂammatory bowel disease,”
New England Journal of Medicine, vol. 361, no. 21, pp. 2066–
2078, 2009.
[2] M.Rutter,B.Saunders,K.Wilkinsonetal.,“Severityofinﬂam-
mation is a risk factor for colorectal neoplasia in ulcerative
colitis,” Gastroenterology, vol. 126, no. 2, pp. 451–459, 2004.
[3] R. B. Gupta, N. Harpaz, S. Itzkowitz et al., “Histologic inﬂam-
mation is a risk factor for progression to colorectal neoplasia
in ulcerative colitis: a cohort study,” Gastroenterology, vol. 133,
no. 4, pp. 1099–1105, 2007.
[ 4 ] J .A .E a d e n ,K .R .A b r a m s ,a n dJ .F .M a y b e r ry ,“T h er i s ko fc o l -
orectal cancer in ulcerative colitis: a meta-analysis,” Gut, vol.
48, no. 4, pp. 526–535, 2001.
[5] J .A.A skling,P .W .Dickman,P .K arlenetal.,“F amilyhist oryas
a risk factor for colorectal cancer in inﬂammatory bowel dis-
ease,” Gastroenterology, vol. 120, no. 6, pp. 1356–1362, 2001.
[6] U. A. Heuschen, U. Hinz, E. H. Allemeyer et al., “Backwash
ileitisisstronglyassociatedwithcolorectalcarcinomainulcer-
ative colitis,” Gastroenterology, vol. 120, no. 4, pp. 841–847,
2001.
[7] A.Ekbom,C.H elmick,M.Zack,andH.O .A dami,“Ulc erati v e
colitis and colorectal cancer: a population-based study,” New
England Journal of Medicine, vol. 323, no. 18, pp. 1228–1233,
1990.
[8] J. Torres, G. P. de Chambrun, S. Itzkowitz, D. B. Sachar, and J.
F. Colombel, “Review article: colorectal neoplasia in patients
with primary sclerosing cholangitis and inﬂammatory bowel
disease,” Alimentary Pharmacology and Therapeutics, vol. 34,
no. 5, pp. 497–508, 2011.
[9] P. M. Choi and M. P. Zelig, “Similarity of colorectal cancer
of Crohn’s disease and ulcerative colitis: implications for car-
cinogenesis and prevention,” Gut, vol. 35, no. 7, pp. 950–954,
1994.
[10] J. E. Lennard-Jones, B. C. Morson, J. K. Ritchie, and C. B.
Williams,“Cancer surveillance inulcerative colitis.Experience
over 15 years,” The Lancet, vol. 2, no. 8342, pp. 149–152, 1983.
[11] J.M.RhodesandB.J.Campbell,“Inﬂammationandcolorectal
cancer:IBD-associatedandsporadiccancercompared,”Trends
in Molecular Medicine, vol. 8, no. 1, pp. 10–16, 2002.
[12] A. Ahmadi, S. Polyak, and P. V. Draganov, “Colorectal cancer
surveillance in inﬂammatory bowel disease: the search contin-
ues,” World Journal of Gastroenterology, vol. 15, no. 1, pp. 61–
66, 2009.
[13] C. H. Koehne and R. N. Dubois, “COX-2 inhibition and col-
orectal cancer,” Seminarsin Oncology, vol. 31, no. 7, pp. 12–21,
2004.
[14] C. V. Rao and B. S. Reddy, “NSAIDs and chemoprevention,”
Current Cancer Drug Targets, vol. 4, no. 1, pp. 29–42, 2004.
[ 1 5 ]R .M a t u k ,J .C r a w f o r d ,M .T .A b r e u ,S .R .T a r g a n ,E .A .
Vasiliauskas, and K. A. Papadakis, “The spectrum of gastro-
intestinal toxicity and eﬀect on disease activity of selective
cyclooxygenase-2 inhibitors in patients with inﬂammatory
bowel disease,” Inﬂammatory Bowel Diseases,v o l .1 0 ,n o .4 ,p p .
352–356, 2004.
[16] L. A. Feagins and B. L. Cryer, “Do non-steroidal anti-inﬂam-
matory drugs cause exacerbations of inﬂammatory bowel dis-
ease?” Digestive Diseases and Sciences, vol. 55, no. 2, pp. 226–
232, 2010.
[17] D.T.Rubin,A.LoSavio,N.Yadron,D.Huo,andS.B.Hanauer,
“Aminosalicylate therapy in the prevention of dysplasia and
colorectal cancer in ulcerative colitis,” Clinical Gastroenterol-
ogy and Hepatology, vol. 4, no. 11, pp. 1346–1350, 2006.
[18] F. S. Velayos, J. P. Terdiman, and J. M. Walsh, “Eﬀect of 5-
aminosalicylate use on colorectal cancer and dysplasia risk: a
systematic review and metaanalysis of observational studies,”
AmericanJournalofGastroenterology,vol.100,no.6,pp.1345–
1353, 2005.
[19] C. N. Bernstein, Z. Nugent, and J. F. Blanchard, “5-amino-
salicylate is not chemoprophylactic for colorectal cancer in
IBD: a population based study,” American Journal of Gastroen-
terology, vol. 106, no. 4, pp. 731–736, 2011.Journal of Biomedicine and Biotechnology 5
[20] A. Lyakhovich and C. Gasche, “Systematic review: molecular
chemoprevention of colorectal malignancy by mesalazine,”
Alimentary Pharmacology and Therapeutics,v o l .3 1 ,n o .2 ,p p .
202–209, 2010.
[21] A. Reinacher-Schick, F. Seidensticker, S. Petrasch et al., “Me-
salazine changes apoptosis and proliferation in normal muco-
sa of patients with sporadic polyps of the large bowel,” Endo-
scopy, vol. 32, no. 3, pp. 245–254, 2000.
[22] P. J. Bus, I. D. Nagtegaal, H. W. Verspaget et al., “Mesalazine-
induced apoptosis of colorectal cancer: on the verge of a new
chemopreventive era?” Alimentary Pharmacology and Ther-
apeutics, vol. 13, no. 11, pp. 1397–1402, 1999.
[23] I. Ikeda, A. Tomimoto, K. Wada et al., “5-Aminosalicylic
acid given in the remission stage of colitis suppresses colitis-
associated cancer in a mouse colitis model,” Clinical Cancer
Research, vol. 13, no. 21, pp. 6527–6531, 2007.
[24] M. L. Clapper, M. A. Gary, R. A. Coudry et al., “5-amino-
salicylic acid inhibits colitis-associated colorectal dysplasias in
the mouse model of azoxymethane/dextran sulfate sodium-
induced colitis,” Inﬂammatory Bowel Diseases, vol. 14, no. 10,
pp. 1341–1347, 2008.
[25] A. Reinacher-Schick, A. Schoeneck, U. Graeven, I. Schwarte-
Waldhoﬀ, and W. Schmiegel, “Mesalazine causes a mitotic
arrest and induces caspase-dependent apoptosis in colon
carcinoma cells,” Carcinogenesis, vol. 24, no. 3, pp. 443–451,
2003.
[26] C. Stolﬁ, D. Fina, R. Caruso et al., “Cyclooxygenase-2-depend-
ent and -independent inhibition of proliferation of colon can-
cer cells by 5-aminosalicylic acid,” Biochemical Pharmacology,
vol. 75, no. 3, pp. 668–676, 2008.
[27] C.Stolﬁ,D.Fina,R.Carusoetal.,“Mesalazinenegativelyregu-
lates CDC25A protein expression and promotes accumulation
of colon cancer cells in S phase,” Carcinogenesis, vol. 29, no. 6,
pp. 1258–1266, 2008.
[28] G.I.Shapiro,“Cyclin-dependentkinasepathwaysastargetsfor
cancer treatment,” Journal of Clinical Oncology, vol. 24, no. 11,
pp. 1770–1783, 2006.
[ 2 9 ]M .G .L u c i a n i ,C .C a m p r e g h e r ,J .M .F o r t u n e ,T .A .K u n k e l ,
and C. Gasche, “5-ASA aﬀects cell cycle progression in col-
orectal cells by reversibly activating a replication checkpoint,”
Gastroenterology, vol. 132, no. 1, pp. 221–235, 2007.
[ 3 0 ]P .J .K o e l i n k ,M .A .C .M i e r e m e t - O o m s ,W .E .C o r v e re ta l . ,
“5-Aminosalicylic acid interferes in the cell cycle of colorectal
cancer cells and induces cell death modes,” Inﬂammatory
Bowel Diseases, vol. 16, no. 3, pp. 379–389, 2010.
[ 3 1 ]B .B a a n ,A .A .D i h a l ,E .H o ﬀ et al., “5-aminosalicylic acid in-
hibits cell cycle progression in a phospholipase D dependent
manner in colorectal cancer,” Gut. In press.
[32] C. Lengauer, K. W. Kinzler, and B. Vogelstein, “Genetic insta-
bilities in human cancers,” Nature, vol. 396, no. 6712, pp. 643–
649, 1998.
[33] Y. Ionov, M. A. Peinado, S. Malkhosyan, D. Shibata, and M.
Perucho, “Ubiquitous somatic mutations in simple repeated
sequencesrevealanewmechanismforcoloniccarcinogenesis,”
Nature, vol. 363, no. 6429, pp. 558–561, 1993.
[34] C. Gasche, A. Goel, L. Natarajan, and C. R. Boland, “Mesal-
azine improves replication ﬁdelity in cultured colorectal cells,”
Cancer Research, vol. 65, no. 10, pp. 3993–3997, 2005.
[ 3 5 ]C .C a m p r e g h e r ,C .H o n e d e r ,H .C h u n g ,J .M .C a r e t h e r s ,a n d
C. Gasche, “Mesalazine reduces mutations in transforming
growth factor β receptor II and activin type II receptor by
improvement of replication ﬁdelity in mononucleotide re-
peats,” Clinical Cancer Research, vol. 16, no. 6, pp. 1950–1956,
2010.
[36] M. B. Kastan and J. Bartek, “Cell-cycle checkpoints and
cancer,” Nature, vol. 432, no. 7015, pp. 316–323, 2004.
[37] M. Bienz and H. Clevers, “Linking colorectal cancer to Wnt
signaling,” Cell, vol. 103, no. 2, pp. 311–320, 2000.
[38] C. L. Bos, S. H. Diks, J. C. Hardwick, K. V. Walburg, M. P.
Peppelenbosch, and D. J. Richel, “Protein phosphatase 2A is
required for mesalazine-dependent inhibition of Wnt/β-cat-
enin pathway activity,” Carcinogenesis, vol. 27, no. 12, pp.
2371–2382, 2006.
[39] M. J. Ratcliﬀe, K. Itoh, and S. Y. Sokol, “A positive role for the
PP2A catalytic subunit in Wnt signal transduction,” Journal of
Biological Chemistry, vol. 275, no. 46, pp. 35680–35683, 2000.
[ 4 0 ]R .N .J o r i s s e n ,F .W a l k e r ,N .P o u l i o t ,T .P .J .G a r r e t t ,C .W .
W a r d ,a n dA .W .B u r g e s s ,“ E p i d e r m a lg r o w t hf a c t o rr e c e p t o r :
mechanisms of activation and signalling,” Experimental Cell
Research, vol. 284, no. 1, pp. 31–53, 2003.
[41] M. Svrcek, J. Cosnes, E. Tiret, M. Bennis, Y. Parc, and
J. F. Fl´ ejou, “Expression of epidermal growth factor receptor
(EGFR) is frequent in inﬂammatory bowel disease (IBD)-
associated intestinal cancer,” Virchows Archiv, vol. 450, no. 2,
pp. 243–244, 2007.
[42] J. P. Spano, C. Lagorce, D. Atlan et al., “Impact of EGFR ex-
pression on colorectal cancer patient prognosis and survival,”
Annals of Oncology, vol. 16, no. 1, pp. 102–108, 2005.
[43] G. Monteleone, L. Franchi, D. Fina et al., “Silencing of SH-
PTP2 deﬁnes a crucial role in the inactivation of epidermal
growth factor receptor by 5-aminosalicylic acid in colon can-
cercells,”CellDeathandDiﬀerentiation,vol.13,no.2,pp.202–
211, 2006.
[44] M. W. Matthiessen, G. Pedersen, T. Albrektsen, S. Adamsen, J.
Fleckner, and J. Brynskov, “Peroxisome proliferator-activated
receptor expression and activation in normal human colonic
epithelial cells and tubular adenomas,” Scandinavian Journal
of Gastroenterology, vol. 40, no. 2, pp. 198–205, 2005.
[45] T. Tanaka, H. Kohno, S. I. Yoshitani et al., “Ligands for per-
oxisomeproliferator-activatedreceptorsαandγ inhibitchem-
ically induced colitis and formation of aberrant crypt foci in
rats,” Cancer Research, vol. 61, no. 6, pp. 2424–2428, 2001.
[46] E. Osawa, A. Nakajima, K. Wada et al., “Peroxisome pro-
liferator-activated receptor γ ligands suppress colon carcino-
genesis induced by azoxymethane in mice,” Gastroenterology,
vol. 124, no. 2, pp. 361–367, 2003.
[47] C. Rousseaux, B. Lefebvre, L. Dubuquoy et al., “Intestinal
antiinﬂammatory eﬀect of 5-aminosalicylic acid is dependent
on peroxisome proliferator-activated receptor-γ,” Journal of
Experimental Medicine, vol. 201, no. 8, pp. 1205–1215, 2005.
[48] P. Desreumaux and S. Ghosh, “Review article: mode of action
anddeliveryof5-aminosalicylicacid—newevidence,”Alimen-
tary Pharmacology and Therapeutics, vol. 24, no. 1, pp. 2–9,
2006.
[49] M. Schwab, V. Reynders, S. Loitsch et al., “PPARγ is involved
in mesalazine-mediated induction of apoptosis and inhibition
ofcellgrowthincoloncancercells,”Carcinogenesis,vol.29,no.
7, pp. 1407–1414, 2008.
[50] C. Stolﬁ, M. Sarra, R. Caruso et al., “Inhibition of colon car-
cinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a
novelderivativeofmesalamine,”Gastroenterology,vol.138,no.
1, pp. 221–230, 2010.
[51] C. Stolﬁ, R. Caruso, E. Franz` e et al., “2-methoxy-5-amino-N-
hydroxybenzamide, a novel derivative of mesalamine, sensi-
tizescoloncancercellstotrail-inducedapoptosisbyregulating
death receptor 5 and survivin expression,” Molecular Cancer
Therapeutics, vol. 10, no. 10, pp. 1969–1981, 2011.6 Journal of Biomedicine and Biotechnology
[52] A. Almasan and A. Ashkenazi, “Apo2L/TRAIL: apoptosis sig-
naling,biology,andpotentialforcancertherapy,”Cytokine and
Growth Factor Reviews, vol. 14, no. 3-4, pp. 337–348, 2003.
[53] M. Lu, A. Strohecker, F. Chen et al., “Aspirin sensitizes cancer
cells to TRAIL-induced apoptosis by reducing survivin levels,”
Clinical Cancer Research, vol. 14, no. 10, pp. 3168–3176, 2008.
[54] C.Honeder, C.Campregher, B. Zens, T.Scharl, and C.Gasche,
“Improvement of replication ﬁdelity by certain mesalazine
derivatives,” International Journal of Oncology, vol. 40, no. 5,
pp. 1331–1338, 2012.